Preclinical development of siRNA therapeutics for AL amyloidosis. - Wikidata - awgldk - TriplyDB

Preclinical development of siRNA therapeutics for AL amyloidosis.

Preclinical development of siRNA therapeutics for AL amyloidosis.

http://www.wikidata.org/entity/Q42867066

about

The Prevalence and Management of Systemic Amyloidosis in Western Countries Update on treatment of light chain amyloidosis Amyloid formation in light chain amyloidosis Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis.Current perspectives on cardiac amyloidosis.Targeting protein aggregation for the treatment of degenerative diseases Immunoglobulin light chain amyloidosis.Novel strategies for the diagnosis and treatment of cardiac amyloidosis.siRNA targeting the κ light chain constant region: preclinical testing of an approach to nonfibrillar and fibrillar light chain deposition diseases.Systemic amyloidosis: novel therapies and role of biomarkers.Viewing Extrinsic Proteotoxic Stress Through the Lens of Amyloid Cardiomyopathy.Plasmocytoma-induced intertriginous amyloid purpura.Light chain amyloidosis: the heart of the problem.Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis.

P2860

Q26740436-0641400E-28CB-44E7-87C1-A27FD403EA37 Q26829735-8598E77C-3E08-4F7D-92E9-FEDE5D49C21F Q27022257-0288DCD5-8034-43B6-9AB7-35FA646AF56E Q35623662-61C288B9-0E80-429A-857E-8E2441D34B21 Q35964900-E5551AE5-ACDA-421C-82CC-9C898B8C3FB9 Q36235980-2B83A4DB-5C3C-4453-9225-1A1B5A4FDA0A Q38172295-5B0C8D61-28C1-405A-8D5C-71340F3EF049 Q38614967-05D18115-2884-444B-B757-FAE39F6701E5 Q38759595-87E8DEE9-1ED1-4C90-BAB2-84DA3072FA1A Q38829923-2C9246C1-67A2-4C47-A448-2466F82DB0BF Q38851025-3CA1281F-BF16-48C7-9526-7C7732415722 Q41763870-FB7EE85E-70B0-4493-AE4C-7A64B606471F Q42958777-3CF91C3C-61D9-4E7B-B30E-50EEE7C21C68 Q47404960-AD89383E-517E-4EE3-840E-4774050A25B9

P2860

Preclinical development of siRNA therapeutics for AL amyloidosis.

http://www.wikidata.org/entity/Q42867066

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Preclinical development of siRNA therapeutics for AL amyloidosis.

@en

Preclinical development of siRNA therapeutics for AL amyloidosis.

@nl

type

label

Preclinical development of siRNA therapeutics for AL amyloidosis.

@en

Preclinical development of siRNA therapeutics for AL amyloidosis.

@nl

prefLabel

Preclinical development of siRNA therapeutics for AL amyloidosis.

@en

Preclinical development of siRNA therapeutics for AL amyloidosis.

@nl

P1433

Q42867066-23A7BE2F-A427-4676-B747-D527E1617DAF

P1476

Q42867066-363DAED8-745F-4B21-9DCA-93AF9E909A99

P2093

Q42867066-268A3717-6016-4CE0-9183-AC11689DF50F

Q42867066-4054BF57-3FD9-4E09-A0BE-2EEFE6D27D4A

Q42867066-861904FE-19D0-4613-BD95-3D7F24BFDE96

Q42867066-C9966AD0-52B6-4CE3-8EDC-121862339790

P2860

Q42867066-05C7D35A-BCF9-4209-B5BE-D9CCDAC4753F

Q42867066-08C9E7CC-A4DE-4B3B-B79D-876BE65273F9

Q42867066-0ACAFFE4-6C16-4729-AFA8-78B50D182FA7

Q42867066-0CDEF1D6-69A9-4494-B514-6CB6216413C5

Q42867066-292EABC2-2962-4C29-B449-CF6799AF7000

Q42867066-2A4E9612-DABD-48F1-9654-B871A27049ED

Q42867066-2D31D1EE-A145-4A69-9938-2A0235B4E305

Q42867066-3659D71D-63C4-4931-A560-759FD8F7F4EE

Q42867066-3A0CCE09-BEFD-49ED-8697-5CE2735D9CAB

Q42867066-3F5CC4CE-C01A-48CD-AAC7-C8CD7684D9AB

P2888

Q42867066-D6A92228-79F3-43D1-8603-B1B5B92D5C29

P304

Q42867066-7B650AF3-88BD-4B7E-B1DE-724559EBCAC8

P31

Q42867066-0490088D-0B7E-4D1F-B9D6-B2929164FF83

P356

Q42867066-5A97B22B-BDA5-4917-9765-FA12F284DC10

P433

Q42867066-F5C80F61-C41C-42BE-BA2B-5405B3C9B33E

P478

Q42867066-5D771C0D-F2E3-4A98-AF8B-F235B194C3E8

P50

Q42867066-6BF49D15-B942-4340-B409-41276C887D25

Q42867066-BD97016C-20D5-431E-AAB3-E4AA36AD64B2

P577

Q42867066-C3359ABF-B865-495F-8B39-03EA2CEC5618

P5875

Q42867066-F97FBF41-C4EE-4049-8A08-8B6307635107

P6179

Q42867066-B43D4BA6-2333-45E0-96DF-592EB32E8D9E

P698

Q42867066-D39CCC63-905C-4057-8EF1-53EBF74C897D

P932

Q42867066-2BB5BE3E-E558-49EF-B4F0-54DC6BFAD1A9

P356

P1433

P1476

Preclinical development of siRNA therapeutics for AL amyloidosis

@en

P2093

B M Hovey

http://www.w3.org/2001/XMLSchema#string

C J O'Hara

http://www.w3.org/2001/XMLSchema#string

D C Seldin

http://www.w3.org/2001/XMLSchema#string

P Soo Hoo

http://www.w3.org/2001/XMLSchema#string

P2860

Statistical analysis of real-time PCR data

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

RAG-1-deficient mice have no mature B and T lymphocytes

Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease.

Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease.

Light-chain (AL) amyloidosis: diagnosis and treatment.

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis.

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.

Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.

Knockdown of the bovine prion gene PRNP by RNA interference (RNAi) technology.

P2888

P304

1150-1156

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/GT.2011.69

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Lawreen H Connors

Jennifer Ellis Ward

P577

2011-05-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51117495

http://www.w3.org/2001/XMLSchema#string

P6179

1001000957

http://www.w3.org/2001/XMLSchema#string

P698

21562591

http://www.w3.org/2001/XMLSchema#string

P932

3155733

http://www.w3.org/2001/XMLSchema#string